tbuckley/cabot-search huggingface dataset:
The close link between anxiety and cluster symptoms in lung cancer patients during first-line chemotherapy: further data from a dedicated WALCE (Women Against Lung Cancer in Europe) survey
Authors: S. Carnio, D. Galetta, V. Scotti, D.L. Cortinovis, A. Antonuzzo, S. Pisconti, A. Rossi, O. Martelli, F.L. Cecere, A. Lunghi, A. Del Conte, E.S. Montagna, J. Topulli, D. Pelizzoni, S.G. Rapetti, M. Gianetta, M.V. Pacchiana, V. Pegoraro, N. Cataldo, E. Bria, S. Novello
Journal: Annals of Oncology (2017)
EPID-01. GLIOBLASTOMA TREATMENT OF BEVACIZUMAB ERA IN KANSAI REGION, JAPAN
Authors: Kanji Mori, Tomoko Shofuda, Yoshiko Okita, Hideyuki Arita, Manabu Kinoshita, Yuzo Terakawa, Naohiro Tsuyuguchi, Yusuke Tomogane, Junya Fukai, Kenichi Ishibashi, Namiko Nishida, Takuyu Taki, Masahiro Nonaka, Shuichi Izumoto, Shusuke Moriuchi, Yoshikazu Nakajima, Naoya Hashimoto, Yoshinori Kodama, Takanori Hirose, Yonehiro Kanemura
Journal: Neuro-Oncology (2017)

Randomized trials failed to prove the efficacy of Bevacizumab on OS of newly diagnosed glioblastomas, but improvement of PFS was revealed. Based on these results, Japanese national health insurance approved Bevacizumab (Bev) for both primary and recurrent glioblastoma treatment in 2013. And at same period, BCNU wafer was also able to be administered. The objective of this study was to examine the influence upon treatment of Glioblastoma that these new therapeutic modalities had, and to find the most popular treatment for glioblastomas in Kansai region, Japan. For this purpose, we retrospectively reviewed clinical data of 223 newly diagnosed glioblastoma patients which were collected for molecular biological analysis by Kansai Molecular Diagnosis Network for CNS Tumors between 2006 and 2016. We examined how treatments of glioblastoma altered after 2013. In 79 patients diagnosed before June 2013, 68 (86.1%) were received concomitant chemoradiotherapy (CCRT) with temozolomide (TMZ), three (3.8%) radiation therapy (RT) only, four (5.1%) chemotherapy (CMT) only, and four (5.1%) none. In 144 patients after that, 113 (78.5%) were received CCRT, six (4.2%) RT only, 19 (13.8%) CMT only, and six (4.2%)none. Bevacizumab was used for 29 patients (20.1%) at initial treatment, 21 (14.6%) at recurrence, and 13 (9.0%) throughout. That is, only about half of glioblastoma patients were treated with Bev. We also found that TMZ were still most frequently used for treatment after recurrence, and nitrosourea was not used at all since 2013. Significant alterations observed were increase of TMZ chemotherapy without RT and use of reduced radiation dose, which were mainly selected based on methylation status of MGMT promoter and patients’ age. Finally, it seems that more personalized treatment for glioblastoma has been introducing in these days, but additional treatment resulting to improvement of prognosis has not become popular.
A three-talk model for shared decision making: multistage consultation process
Authors: Glyn Elwyn, Marie Anne Durand, Julia Song, Johanna Aarts, Paul J Barr, Zackary Berger, Nan Cochran, Dominick Frosch, Dariusz Galasiński, Pål Gulbrandsen, Paul K J Han, Martin Härter, Paul Kinnersley, Amy Lloyd, Manish Mishra, Lilisbeth Perestelo-Perez, Isabelle Scholl, Kounosuke Tomori, Lyndal Trevena, Holly O Witteman, Trudy Van der Weijden
Journal: BMJ (2017)

Objectives To revise an existing three-talk model for learning how to achieve shared decision making, and to consult with relevant stakeholders to update and obtain wider engagement.Design Multistage consultation process.Setting Key informant group, communities of interest, and survey of clinical specialties.Participants 19 key informants, 153 member responses from multiple communities of interest, and 316 responses to an online survey from medically qualified clinicians from six specialties.Results After extended consultation over three iterations, we revised the three-talk model by making changes to one talk category, adding the need to elicit patient goals, providing a clear set of tasks for each talk category, and adding suggested scripts to illustrate each step. A new three-talk model of shared decision making is proposed, based on "team talk," "option talk," and "decision talk," to depict a process of collaboration and deliberation. Team talk places emphasis on the need to provide support to patients when they are made aware of choices, and to elicit their goals as a means of guiding decision making processes. Option talk refers to the task of comparing alternatives, using risk communication principles. Decision talk refers to the task of arriving at decisions that reflect the informed preferences of patients, guided by the experience and expertise of health professionals.Conclusions The revised three-talk model of shared decision making depicts conversational steps, initiated by providing support when introducing options, followed by strategies to compare and discuss trade-offs, before deliberation based on informed preferences.
Cost-effectiveness of Strategies for Offering Influenza Vaccine in the Pediatric Emergency Department
Authors: Rebecca J. Hart, Michelle D. Stevenson, Michael J. Smith, A. Scott LaJoie, Keith Cross
Journal: JAMA Pediatrics (2017)

Influenza is a significant public health burden, causing morbidity and mortality in children, yet vaccination rates remain low. Vaccination in the pediatric emergency department (PED) setting may be beneficial but, to date, has not been proven to be cost-effective.To compare the cost-effectiveness of 4 strategies for PED-based influenza vaccine: offering vaccine to all patients, only to patients younger than 5 years, only to high-risk patients (all ages), or to no patients.Using commercial decision analysis software, a cost-effectiveness analysis was performed from January 1, 2016, to June 1, 2017, to compare influenza vaccine strategies at a tertiary, urban, freestanding PED with an estimated 60 000 visits per year among a hypothetical cohort of children visiting the above PED during influenza season. Sensitivity analyses estimated the effect of uncertainties across a variety of input variables (eg, influenza prevalence, vaccine price and effectiveness, and costs of complications).The primary outcomes were cost and incremental cost-effectiveness ratio in dollars per influenza case averted. Secondary outcomes included total societal costs, hospitalizations and deaths averted, and quality-adjusted life-years gained.Offering influenza vaccine to all eligible patients has the lowest cost, at $114.45 (95% CI, $55.48-$245.45) per case of influenza averted. This strategy saves $33.51 (95% CI, $18-$62) per case averted compared with no vaccination, and averages 27 fewer cases of influenza per 1000 patients. Offering vaccine to all patients resulted in 0.72 days (95% CI, 0.18-1.78 days) of quality-adjusted life-years lost, whereas offering to none resulted in 0.91 days (95% CI, 0.25-2.2 days) of quality-adjusted life-years lost. In sensitivity analyses, this strategy remains robustly cost-effective across a wide range of assumptions. In addition to being the most cost-effective strategy regardless of age or risk status, routine vaccination in the PED results in a net societal monetary benefit under many circumstances. In Monte Carlo analysis, offering vaccine to all patients was superior to other strategies in at least 99.8% of cases.Although few PEDs routinely offer influenza vaccination, doing so appears to be cost-effective, with the potential to significantly reduce the economic (and patient) burden of pediatric influenza.
MA 20.08 Classification of Confocal Endomicroscopy Patterns for Diagnosis of Lung Cancer
Authors: R.M. Ortiz Comino, D. Gil, E. Minchole, M. Diez-Ferrer, N. Cubero, R. Lopez-Lisbona, C. Sanchez, O. Ramos, A. Esteban, J. Dorca, A. Rosell
Journal: Journal of Thoracic Oncology (2017)
Abstract 29: Porcine Decellularized Heart Tissue Enhance the Expression of Contractile Proteins in Human Cardiomyocytes and Differentiated Cardiac Progenitor Cells
Authors: Anne-Cecile Huby, Farideh Beigi, Qian Xiang, Andrea Gobin, Doris Taylor
Journal: Circulation Research (2016)

Tissue engineering is an evolving tool for repair of cardiovascular damage, in particular after myocardial infarction. Currently, most studies are focused on providing gel or thin synthetic matrices to provide structural support for injured valves, or ventricle. But little is known about how cardiac cells (eg, endothelial cells [ECs], cardiomyocytes [CMs] and cardiac progenitor cells [CPCs]) are modified by an exposure to a scaffold much less how a xenogeneic scaffold may affect cell physiology or function. Our study was designed to examine the effect of rat or pig collagen matrix and decellularized left ventricle extracellular matrix (dECM) tissues on the phenotype of human cardiac cells. Human ECs, CMs and CPCs derived from IPs cells (Cellular Dynamics International) were cultured singly or together on rat or pig collagen matrices or on dECM. Protein and gene expression was investigated by immunohistochemistry, histology and real time PCR. All 3 cell types survived on both types of support when delivered singly or together. Endothelial cell PECAM-1 expression was enhanced on decellularized tissues particularly on rat matrix. Cardiomyocyte contractile protein expression did not differ with support type, whereas CPC contractile protein gene expression increased on both decellularized tissues more so on pig matrix. Additionally, when the cells were co-cultured, single cell type gene expression was modified. Our study showed that human cardiac cells are influenced by the structural support on which they are cultivated. Cardiac ECM enhanced the expression of contractile proteins and endothelial markers but matrix species had minimal influence on this effect. Furthermore, cell co-culture altered gene expression suggesting cell communication is intact on the matrix. This study shows that cell phenotype and behavior is impacted by the tissue matrix to a greater degree than occurs with a simple one protein support and suggests complex decellularized matrix may be superior to successfully engineer cardiac constructs with intact physiology. Additionally, the successful differentiation of IPs cells into cardiomyocytes on decellularized matrix opens avenue to build tissue engineer constructs from patients with heart disease as a screening tool.
Abstract 13807: The Triglyceride to High-Density Lipoprotein Cholesterol Ratio Predicts Coronary Artery Disease in Non-Diabetic Individuals
Authors: Julian Gin, Natalie Yap, Anke Nguyen, Heath Adams, Andrew Wilson
Journal: Circulation (2014)

Introduction:  Insulin resistance is a risk factor for coronary artery disease (CAD) and is associated with a characteristic pro-atherogenic dyslipidemia. The triglyceride/high-density lipoprotein cholesterol (TG:HDLC) ratio has been shown to be a good surrogate marker of insulin resistance, which develops before Type II Diabetes Mellitus is diagnosed. Given this, it may be clinically useful to have a means to identify non-diabetics with coronary disease.   Hypothesis:  We assessed the hypothesis that a high TG:HDLC ratio predicts coronary artery disease in high-risk cardiovascular patients without Type II Diabetes Mellitus.   Methods:  We analyzed 614 non-diabetic individuals from the larger BRAVEHEART Cohort Study presenting for coronary angiography. Cardiac risk factors were assessed, and fasting insulin, fasting blood glucose, glycated hemoglobin and a full lipid panel were collected. A TG:HDLC ratio was measured in 594 patients. Patients were categorized according to 1) the presence or absence of CAD, and 2) 0 vessel (CAD absent), 1&2 vessel, or 3 vessel disease.   Results:  The mean TG:HDLC ratio was greater in those with CAD than those without (1.61±0.06 [standard error], 95% confidence interval [CI] 1.49-1.73 vs. 1.20±0.05, 95% CI 1.10-1.30;  p =0.0001). Compared to 0-vessel disease, both 1&2 and 3-vessel groups had a higher mean TG:HDLC (1.20±0.05 vs. 1.60±0.1 95% CI 1.40-1.80 & 1.62±0.06, 95% CI 1.49-1.79 respectively;  p  p =0.1596). Logistic regression analysis showed that the TG:HDLC ratio was a statistically significant predictor of the presence of any CAD (Odds Ratio [OR]=1.83±0.33; 95% CI 1.28-2.59,  p =0.001) adjusted for statin use, lipids, glycemic markers, insulin and cardiac risk factors.   Conclusion:  In conclusion, these results suggest that the TG:HDLC ratio positively predicts CAD in non-diabetic individuals presenting for angiography independent of statin use, lipids, glucose and insulin levels, and cardiac risk factors. Although these results show potential for clinical application, further studies are warranted to investigate whether the TG: HDL ratio will be useful to screen high-risk patients.
QLIF-09. LONGTERM SURVIVAL IN GLIOBLASTOMA PATIENTS AFTER TUMOR TREATING FIELDS (TTFIELDS) THERAPY
Authors: Aaron Rulseh, Jan Sroubek, Jan Klener, Josef Vymazal
Journal: Neuro-Oncology (2017)

Glioblastoma (GBM) is the most common and malignant primary intracranial tumor and traditionally has a median survival of only 10 to 14 months, with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM) is nearly universal, and further decreases the median survival to only 5 to 7 months with optimal therapy. Tumor treating fields (TTFields; Optune™) therapy is a novel treatment technique that has recently shown significant prolonged progression free survival and overall survival in newly diagnosed GBM. This therapy is approved for the treatment of newly diagnosed and recurrent GBM and is based on the principle that low intensity, intermediate frequency alternating electric fields (100 to 300 kHz) have an anti-mitotic effect in specific cell types. The applied fields disrupt the mitotic spindle, microtubule assembly and the segregation of intracellular organelles during cell division, leading to apoptosis or mitotic arrest. Our center was the first in the world to apply TTFields treatment to histologically proven GBM in a small pilot study of 20 individuals (10 GBM and 10 RGBM) in 2004 and 2005, and 4 of the original 20 patients are still alive today (2 GBM, 2 RGBM), in good health and no longer receiving any treatment roughly 12 years after initiating TTFields therapy, with no clinical or radiological evidence of recurrence. Two of the 4 surviving patients exhibited radiological signs of tumor growth initially, before the tumor regressed in size after a median of 4 months of continuous treatment. Our results indicate that TTFields treatment may be remarkably successful for both newly diagnosed and recurrent GBM patients. We recommend that TTFields treatment should be applied for a sufficient amount of time, and that initial radiologic progression following treatment initiation should not be considered a reason to discontinue treatment.
P2.03-024 Phase II Trial of AZD9291 in Second-Line Treatment after Acquired Resistance with T790M Mutation Detected From Circulating Tumor DNA
Authors: Y. Kim, C. Park, I. Oh, J. Lim, Y. Choi, H. Cho, S. Ahn, S. Song, J.S. Yun, K. Na, S. Kim, H. Park
Journal: Journal of Thoracic Oncology (2017)
SURG-22. QUALITY BASED ASSESSMENT OF THE COST-EFFECTIVENESS OF 5-ALA IN HIGH GRADE GLIOMA SURGERY: A SYSTEMATIC REVIEW
Authors: Rahel Zewude, Laureen Hachem, Alireza Mansouri
Journal: Neuro-Oncology (2017)

High grade gliomas (HGG) are the most common primary malignant brain tumors in adults. While the infiltrative nature of HGG makes safe maximal resections challenging, studies on the use of adjuncts such as 5-ALA have shown much promise. The accumulating clinical evidence has led to approval of 5-ALA for clinical practice in Europe but not in North America. Prior to integration into routine practice, data on the health economic impact of novel agents are considered by regulatory health agencies. With respect to 5-ALA, this evidence is limited and requires further investigation. A systematic review and synthesis of the state of evidence on health economic assessment of 5-ALA in HGG surgery was conducted. Medline, EMBASE, CRD, EconPapers and Cochrane databases were searched for keywords related to glioma, cost-effectiveness and 5-ALA. Three primary studies were identified (1 Portuguese, 1 Spanish and 1 French). One measured incremental cost-effectiveness ratio (ICER) of 5-ALA per gained Quality Adjusted Life Year (QALY) compared to white light surgery. Another assessed cost-effectiveness based on incremental cost per QALY and per complete resection. The first study reported ICER of €9100/ QALY while the second reported €9021/QALY. Both studies reported that 5-ALA was well below their respective national cost-effectiveness thresholds. The third study compared glioblastoma (GBM) surgical costs during a period before 5-ALA’s introduction and after it started being widely used. The difference in average costs of GBM surgery during these periods, €9353 compared to €10,118, was not significant. None of these studies considered patient’s perspective and indirect costs in their analysis. While clinical evidence in favor of 5-ALA as intraoperative adjunct is accumulating, health economic data is limited and of low quality. Prospective high quality evaluations on cost-effectiveness of 5-ALA are necessary prior to its regulatory approval and routine clinical use in North America.
P2.02-036 The Expression Pattern of CD26/DPP4 in Human Lung Cancer
Authors: J. Jang, M. Haberecker, C. Alexandra, A. Soltermann, I. Gil-Bazo, F. Janker, K. Kwon, W. Weder, W. Jungraithmayr
Journal: Journal of Thoracic Oncology (2017)
P3.02-066 Wild-Type KRAS Mediates Growth Inhibition and Resistance to MEK Inhibitors through Dimerization with Mutant KRAS in Lung Adenocarcinoma
Authors: C. Ambrogio, J. Kohler, Z. Zhou, H. Wang, R. Paranal, M. Capelletti, C. Caffarra, S. Li, Q. Lv, S. Gondi, J. Hunter, R. Chiarle, D. Santamaría, K. Westover, P. Jänne
Journal: Journal of Thoracic Oncology (2017)
Residency Evaluations—Where Is the Patient Voice?
Authors: Sri Lekha Tummalapalli
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
OA 06.02 Final Report of the INHERIT EGFR Study - 33 Unrelated Kindreds Carrying Germline EGFR Mutations
Authors: G. Oxnard, J. Heng, R. Chen, D. Koeller, K. Shane-Carson, R. Morgan, G. Wiesner, J. Garber
Journal: Journal of Thoracic Oncology (2017)
Sistema de vigilancia de las infecciones por Chlamydia trachomatis y Neisseria gonorrhoeae por los laboratorios de Dinamarca
Authors: S Hoffmann
Journal: Eurosurveillance (2001)

Este articulo presenta los resultados de la vigilancia de infecciones por C. trachomatis y N. gonorrhoeae en Dinamarca. En 1999 y 2000, se registraron 291 y 309 casos masculinos de gonorrea confirmada por laboratorio, mientras que el numero de casos femeninos fue de 43 en ambos anos. La tasa de resistencia a la penicilina se mantuvo constante, con una prevalencia del 40% en 1999, mientras la prevalencia de resistencia a la fluoroquinolona aumento del 0% en 1990 al 27% en 1999. El numero de infecciones por C. trachomatis confirmadas por laboratorio sigue siendo de 13.000 casos al ano. Los varones de 20 a 29 anos y las mujeres de 15 a 24 anos son los grupos de mayor riesgo.
STEM-13. IDENTIFICATION OF NOVEL TARGETS IN GLIOBLASTOMA STEM CELLS THROUGH CRISPR-Cas9 SCREENING
Authors: Qi Xie, Briana Prager, Jeremy Rich
Journal: Neuro-Oncology (2017)

Glioblastoma is the most lethal primary brain tumor, with a median survival of less than 15 months despite maximal therapy. The therapeutic resistance and inevitable recurrence of glioblastoma are driven in large part by glioblastoma stem cells (GSCs). Identifying novel targets that inhibit GSC survival is critical to developing new and effective therapies for GBM and for advancing our understanding of molecular dependencies in GSCs. We therefore performed a CRISPR-Cas9 screen in patient-derived GSC lines to elucidate drivers of GSC viability. To identify candidate genes for the screen, we performed an in silico analysis, interrogating The Cancer Genome Atlas (TCGA). We first stratified by CpG island methylator phenotype (CIMP) status since glioma-CIMP (G-CIMP) tumors appear to have a distinct underlying biology and disease course. We selected genes that were upregulated in either non G-CIMP or G-CIMP tumors vs. normal brain tissue and further filtered this gene set by intersecting it with the list of genes for which higher expression was associated with worse survival in each group. We designed a CRISPR-Cas9 library targeting the selected 536 genes and performed a drop-out screen in five distinct patient-derived GSC lines for genes that are critical for survival and maintenance of GSCs. We then validated top hits by individual CRISPR knockout. Using CRISPR screening technology in patient-derived cell lines, we identified crucial dependencies in patient-derived GSCs. Further experiments will characterize the mechanism of these dependencies and assess their potential therapeutic relevance in pre-clinical models.
CREAM study: Clinical correlation between immunotherapy-RElated colitis And intestinal Microbiote in metastatic patients
Authors: L. Orgiano, A. Cubeddu, R. Mascia, E. Lai, M. Dessì, E. Pedditzi, P. Piredda, E. Saba, V. Palmas, T. Camboni, E. Massa, G. Astara, A. Manzin, C. Madeddu, M. Scartozzi
Journal: Annals of Oncology (2017)
Évaluation épidémiologique et virologique de l’activité grippale en Europe pendant l’hiver 2005-2006
Authors: A Meijer, T J Meerhoff, L. E. Meuwissen, J Van Der Velden, W J Paget
Journal: Eurosurveillance (2007)

L’activite grippale en Europe pendant l’hiver 2005-2006 a commence fin janvier-debut fevrier 2006 et s’est d’abord manifestee aux Pays-Bas, en France, en Grece et en Angleterre.
MA 19.01 A Phase II Study of Nivolumab: A Multicenter, Open-Label, Single Arm Study in Malignant Pleural Mesothelioma (MERIT)
Authors: Y. Goto, M. Okada, T. Kijima, K. Aoe, T. Kato, N. Fujimoto, K. Nakagawa, Y. Takeda, T. Hida, K. Kanai, F. Imamura, S. Oizumi, T. Takahashi, M. Takenoyama, H. Tanaka, Y. Ohe
Journal: Journal of Thoracic Oncology (2017)
NHS will have workforce plan for first time in 17 years, Hunt announces
Authors: Abi Rimmer
Journal: BMJ (2017)

The NHS will have a workforce plan for the first time since 2000, England’s secretary of state for health has announced.

Speaking at the NHS Providers conference in Birmingham on 8 November, Jeremy Hunt said that a draft plan would be published by the end of the year. He said that recent initiatives, such as plans to increase medical student numbers, would form part of a wider NHS workforce …
P2.03-028 Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial
Authors: Y. Shi, X. Hu, S. Zhang, N. Yang, Y. Zhang, W. Li, X. Han, H. Mo, Y. Sun
Journal: Journal of Thoracic Oncology (2017)
P2.03-022 Impact of EGFR Mutation on Clinical Outcome of Nintedanib plus Docetaxel in Previously Treated Non- Small Cell Lung Cancer (NSCLC)
Authors: S. Hong, H.J. Ahn, K.H. Kim, S.S. Lee, Y.G. Lee, Y.J. Yuh, P.I. Cheon, Y.S. Chae, T.W. Jang, J. Kang
Journal: Journal of Thoracic Oncology (2017)